Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan
{{output}}
Background: The 'Questions and Answers (Q&A)' document regarding Japanese biosimilar guideline elucidated that Japanese participant enrollment in at least one comparative clinical study was required for the marketing authorizatio... ...
